Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Patent
1994-10-12
1995-06-06
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
514 3, 514866, A61K 3326, A61K 3726
Patent
active
054221250
ABSTRACT:
A method of treating human or animal patients suffering from insulin resistance syndromes, particularly diabetes mellitus, by administering an effective amount of the compound magnesium vanadate. Daily dosage ranges are preferably from about 2 to about 60 mg per kg of patient body weight. Pharmaceutical compositions for use in the method of treatment include magnesium vanadate and at least one pharmaceutically acceptable inert ingredient, and may be oral, parenteral, transdermal or transmucosal dosage forms containing from about 50 to about 1000 mg of magnesium vanadate per unit.
REFERENCES:
patent: 4217343 (1980-08-01), Gaffar et al.
patent: 4343794 (1982-08-01), Podos et al.
patent: 4882171 (1989-11-01), Posner et al.
patent: 5023358 (1991-06-01), Lazaro et al.
patent: 5164384 (1992-11-01), Paul
Rossetti et al. Diabetes, 39:1243-1250 (1990).
Rossetti et al. J. Clin. Invest., 84:892-899 (1989).
Cordera et al. Endocrinology, 126:2177-2183 (1990).
Blondel et al. Am. J. Physiol., 258:E459-E467 (1990).
Serradas et al. Pancreas, 6:54-62 (1991).
Frost Phillip
Hahn Elliot F.
Skyler Jay S.
Baker Norton Pharmaceuticals, Inc.
Henley III Raymond
LandOfFree
Method and composition for treatment of insulin resistance syndr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for treatment of insulin resistance syndr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treatment of insulin resistance syndr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-985893